SphK2-overexpressing HCC cells (LV-SphK2 HCC cells) exhibited low sensitivity to regorafenib, as determined by the CCK-8 assay (Figure 3B), which was similar to the results demonstrated in HCC cells with acquired regorafenib resistance. Here, SPHK2 is linked to hepatocellular carcinoma.